Trial in Adult Subjects With Acute Migraines

Migraine, With or Without Aura Clinical Trial

Official title:
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03461757
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	February 27, 2018
Completion date	October 15, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02848326` - Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention	Phase 2/Phase 3
Completed	`NCT02873221` - An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine	Phase 3
Completed	`NCT03237845` - Safety and Efficacy in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT02828020` - Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03235479` - Safety and Efficacy Study in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03266588` - Open Label Safety Study in Acute Treatment of Migraine	Phase 2/Phase 3
Completed	`NCT02867709` - Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3